Skip to main
VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals (VNDA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Vanda Pharmaceuticals is well-positioned for long-term success with their anticipated market entry of Bysanti (milsaperidone) in the treatment of bipolar I disorder and schizophrenia, backed by clinical studies and a strong safety profile. With the potential for market exclusivity until 2044, Vanda can also leverage their established infrastructure to effectively launch and incentivize the switch from iloperidone. This added service revenue and high probability of approval make Vanda a strong buy, with a raised 12-month price target of $24 per share.

Bears say

Vanda Pharmaceuticals is facing several risks that could negatively impact its stock, including slower-than-expected sales, generic erosion, negative pricing developments, regulatory setbacks, negative clinical readouts, adverse developments on the M&A front, and potential dilution. These risks, combined with the company's current valuation and high dependence on its Fanapt product, contribute to a negative outlook on the stock. The company's current valuation, projected sales, and potential dilution risks indicate a price objective of $21 per share, but achieving that target is not guaranteed due to the aforementioned risks in the pharmaceutical industry.

Vanda Pharmaceuticals (VNDA) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vanda Pharmaceuticals (VNDA) Forecast

Analysts have given Vanda Pharmaceuticals (VNDA) a Buy based on their latest research and market trends.

According to 5 analysts, Vanda Pharmaceuticals (VNDA) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vanda Pharmaceuticals (VNDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.